Jim Wassil Sells 3,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 3,000 shares of Vaxcyte stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $76.34, for a total transaction of $229,020.00. Following the sale, the chief operating officer now directly owns 210,503 shares of the company’s stock, valued at approximately $16,069,799.02. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jim Wassil also recently made the following trade(s):

• On Monday, June 3rd, Jim Wassil sold 3,000 shares of Vaxcyte stock. The stock was sold at an average price of $71.99, for a total transaction of $215,970.00.

Vaxcyte Price Performance

NASDAQ PCVX opened at $76.26 on Thursday. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $82.04. The firm has a 50-day moving average price of $70.52 and a two-hundred day moving average price of $68.28.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28. On average, research analysts predict that Vaxcyte, Inc. will post -3.96 EPS for the current year.

Wall Street Analyst Weigh In

PCVX has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a report on Friday, June 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th.

Institutional Trading of Vaxcyte

A number of institutional investors have recently bought and sold shares of the business. Xponance Inc. boosted its holdings in Vaxcyte by 3.0% in the 4th quarter. Xponance Inc. now owns 5,672 shares of the company’s stock valued at $356,000 after purchasing an additional 163 shares during the period. Ellsworth Advisors LLC raised its position in shares of Vaxcyte by 2.6% in the 4th quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock valued at $506,000 after buying an additional 207 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after buying an additional 250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vaxcyte by 0.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock valued at $3,211,000 after buying an additional 296 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Vaxcyte by 1.7% in the 4th quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock valued at $1,382,000 after buying an additional 376 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.